Alzheimer's and Dementia


Publication Venue For

  • APOE-ε4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies..  14:1137-1147.
  • Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.  4:421-427.
  • Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort.  16:60-70.
  • Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.  10:349-359.
  • Erratum: Estimating power with effect size versus slope differences: Both means and variance matter (Alzheimer's and Dementia (2011) 7 (247-249)).  7.
  • Estimating power with effect size versus slop differences: Both means and variance matter.  7:247-249.
  • Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development.  9.
  • Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases.  16:118-130.
  • Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses.  11:1439.
  • Implications of early treatment among Medicaid patients with Alzheimer's disease.  10:214-224.
  • Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study.  15:273-281.
  • O3-06-01: Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.  11:P230-P230.
  • Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.  6:367-377.
  • Transethnic genome-wide scan identifies novel Alzheimer's disease loci.  727-738.